CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Subcutaneous progesterone +1 moredrug
Likely dose
Subcutaneous progesterone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02567552
NCT02567552Phase 4Completed
CompareCT.gov

Randomized Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone (Prolutex) 25 mg/Day Versus Intramuscular Progesterone (Prontogest) 50 mg/Day

IVI Barcelona·interventional·Posted Oct 5, 2015·Updated Dec 16, 2019

In Brief

A Phase 4 clinical trial evaluating Subcutaneous progesterone and Intramuscular progesterone for Reproductive Techniques, Assisted. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Study the endometrial predecidualization by using subcutaneous progesterone 25 mg/day versus intramuscular progesterone 50 mg/day, to determine whether there are differences in the endometrial transformation and endometrial receptivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReproductive Techniques, Assisted
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 5, 2015
Enrollment StartMay 1, 2015
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.7 years ago

Interventions

Subcutaneous progesteronedrug

subcutaneous progesterone 25 mg/day

Intramuscular progesteronedrug

intramuscular progesterone 50 mg/day